Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | hypothetical protein | 0.022 | 0.0102 | 0.0102 |
Trypanosoma cruzi | Aph-1 protein, putative | 0.2421 | 0.3737 | 1 |
Echinococcus granulosus | presenilin | 0.0452 | 0.0485 | 0.0387 |
Toxoplasma gondii | hypothetical protein | 0.0158 | 0 | 0.5 |
Echinococcus multilocularis | presenilin enhancer 2 | 0.0425 | 0.0439 | 0.034 |
Echinococcus granulosus | presenilin enhancer 2 | 0.0425 | 0.0439 | 0.034 |
Leishmania major | presenilin-like aspartic peptidase, putative,presenilin-like aspartic peptidase, clan AD, family A22A, putative | 0.0452 | 0.0485 | 0.5 |
Echinococcus granulosus | gamma secretase subunit aph 1 | 0.6214 | 1 | 1 |
Entamoeba histolytica | presenilin 1 peptidase, putative | 0.0452 | 0.0485 | 0.5 |
Trypanosoma brucei | Aph-1 protein, putative | 0.2421 | 0.3737 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.022 | 0.0102 | 0.0102 |
Echinococcus multilocularis | gamma secretase subunit aph 1 | 0.6214 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.022 | 0.0102 | 0.0102 |
Schistosoma mansoni | gamma-secretase subunit aph-1 | 0.6214 | 1 | 1 |
Trypanosoma cruzi | Aph-1 protein, putative | 0.2421 | 0.3737 | 1 |
Loa Loa (eye worm) | gamma-secretase subunit aph-1 | 0.6214 | 1 | 1 |
Echinococcus multilocularis | presenilin | 0.0452 | 0.0485 | 0.0387 |
Brugia malayi | gamma-secretase subunit pen-2 | 0.0425 | 0.0439 | 0.0439 |
Trichomonas vaginalis | Clan AD, family A22, presenilin-like aspartic peptidase | 0.0452 | 0.0485 | 1 |
Trichomonas vaginalis | Clan AD, family A22, presenilin-like aspartic peptidase | 0.0452 | 0.0485 | 1 |
Brugia malayi | Presenilin family protein | 0.0452 | 0.0485 | 0.0485 |
Trichomonas vaginalis | Clan AD, family A22, presenilin-like aspartic peptidase | 0.0452 | 0.0485 | 1 |
Schistosoma mansoni | subfamily A22A unassigned peptidase (A22 family) | 0.0452 | 0.0485 | 0.0387 |
Loa Loa (eye worm) | gamma-secretase subunit pen-2 | 0.0425 | 0.0439 | 0.0439 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.